Michael Har-Noy Founder and CEO of Immunovative Therapies, Ltd
Studying AlloStimTM Along With Chaperone Rich Protein Lysate Dr. Michael Har-Noy, founder and CEO of Immunovative Therapies, Ltd., says that the power of the human immune system can be successfully harnessed to kill malignant tumors and to prevent their recurrence. Dr. Michael Har-Noy says that preliminary data indicates that AlloStimTM, his companyâ€™s lead product, has powerful anti-tumor activity against a wide range of malignancies. Dr. Michael HarNoy is now conducting a Phase I/II trial that combine AlloStimTM with Chaperone Rich Protein Lysate (CRCL). He hopes this combination will both eradicate malignant tumors and prevent their recurrence. More information about Dr. Michael Har-Noyâ€™s landmark phase I/II trial of CRCL-AlloVaxTM can be found at www.immunocare.net.
Compassionate Use Program Is Underway In Bangkok, Thailand Dr. Michael Har-Noy, Immunovative Therapies Ltd.’s CEO and founder, says that patients with metastatic cancer that have exhausted all conventional treatment options may qualify for treatment using his company’s unique biologic products. Dr. Michael Har-Noy indicates that his Compassionate Use program in Bangkok, Thailand is being conducted along with a phase I/II trial of CRCL-AlloVaxTM, one of his company’s leading drugs. Dr. Michael Har-Noy is also testing the drug AlloStimTM in HIV positive patients. Interested parties should visit the website, www.immunocare.net, for more information.
Proprietary Drugs May Be Effective Against Many Different Cancers Preliminary data show that AlloStimTM and CRCL-AlloVaxTM, two proprietary compounds developed by Dr. Michael Har-Noy, have activity against a wide variety of malignancies. Dr. Michael Har-Noy, founder and CEO of Immunovative Therapies Ltd., a biotechnology company in Israel, says that he is planning phase I/II trials of AlloStimTM in hepatocellular carcinoma and in head and neck malignancies. Dr. Michael Har-Noy is also designing phase II/III marketing trials for his drugs in patients with HER2+ breast cancer and KRAS gene positive colon cancer. Please visit www.immunocare.net for more information.